CRBU
NASD Caribou Biosciences, Inc.$0.4602 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.4602, $0.0592 below the day’s high of $0.5194
- YTD change
- -71.06%
- vs 20-day SMA
- -61.19%
- vs 200-day SMA
- -73.30%
Price ranges
Price & Performance
-1.49 (-76.40%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 98.6% away from all-time highs of $32.6450
- CRBU is down 71% since the beginning of the year
- CRBU is down 83% over the past 12 months
- CRBU is down 66% over the past 1 month
- 13% of all CRBU investors are betting against CRBU
CRBU reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -80.7%.
- Previous minute
- -$0.0071
- Last hour
- -$0.0121
- Last 5 days
- -62.28%
- vs 8-day SMA
- -56.03%
No alerts for CRBU in the last day.
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.